(Q44952094)

7 December 2017

title

Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis B. (English)

1 reference

7 December 2017

1 reference

Shin JW

1

1 reference

7 December 2017

Park NH

2

1 reference

7 December 2017

Park JH

3

1 reference

7 December 2017

Park JH

4

1 reference

7 December 2017

Jeong ID

5

1 reference

7 December 2017

Bang SJ

6

1 reference

7 December 2017

Joo KR

7

1 reference

7 December 2017

Kim DH

8

1 reference

7 December 2017

publication date

1 July 2005

1 reference

Journal of Viral Hepatitis

7 December 2017

published in

1 reference

7 December 2017

volume

12

1 reference

7 December 2017

issue

4

1 reference

7 December 2017

page(s)

393-397

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Lamivudine therapy of WHV-infected woodchucks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Hepatitis B genotypes and the response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2005.00606.X

10.1111/J.1365-2893.2005.00606.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference